Get started
Author

Alessandro Previtali

Observed name: A. Previtali
ORCID: 0009-0004-5429-657X
Observed ORCID: 0009-0004-5429-657X
OpenAlex ID: A5085795367
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
2022 · Manali Kamdar, Scott R Solomon, et al. · The Lancet · 805
PDF
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
2022 · Jeremy S. Abramson, Scott R. Solomon, et al. · Blood · 401
PDF
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
2021 · Manali Kamdar, Scott R. Solomon, et al. · Blood · 90
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
2021 · Amer M. Zeidan, Isaac Boss, et al. · Blood Advances · 83
PDF
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
2019 · Amer M. Zeidan, James Cavenagh, et al. · Blood · 80
Critical review of oncology clinical trial design under non-proportional hazards
2021 · Revathi Ananthakrishnan, Stephanie Green, et al. · Critical Reviews in Oncology/Hematology · 36
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
2022 · Jeremy S. Abramson, Patrick B. Johnston, et al. · Blood Advances · 24
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
2022 · Jeremy S. Abramson, Scott R. Solomon, et al. · Blood · 10
Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
2021 · Jeremy S. Abramson, Scott R. Solomon, et al. · Blood · 9
Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study
2017 · Severine Vermeire, Edward V. Loftus, et al. · Gastroenterology · 9
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma
2025 · Jeremy S. Abramson, Manali Kamdar, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
PDF
Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.
2023 · Loretta J. Nastoupil, Manali K. Kamdar, et al. · Journal of Clinical Oncology · 3
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
2022 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 3
DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
2017 · S. Vermeire, E.V. Loftus, et al. · Journal of Crohn s and Colitis · 3
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
2024 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 2
PDF
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
2022 · Manali Kamdar, Scott R. Solomon, et al. · Transplantation and Cellular Therapy · 2
Mo1879 Response and Remission Rates With Up to 3 Years of Vedolizumab Treatment in Patients With Crohn's Disease
2016 · Severine Vermeire, Brian G. Feagan, et al. · Gastroenterology · 2
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
2024 · Jeremy S Abramson, Scott R Solomon, et al. · Future Oncology · 1
PDF
Lisocabtagene Maraleucel (liso‐cel) Versus Standard of Care (soc) as Second‐line Therapy in Large B‐cell Lymphoma (transform Study): Subgroup Analyses by Prior Therapy Response
2023 · L. J. Nastoupil, M. Kamdar, et al. · Hematological Oncology · 1
PDF
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma
2023 · F. Morschhauser, H. Ghesquieres, et al. · Hematological Oncology · 1
PDF
Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
2022 · Jeremy S. Abramson, Scott R. Solomon, et al. · Transplantation and Cellular Therapy · 1
Mo1883 Response and Remission Rates With up to 3 Years of Vedolizumab Treatment in Patients with Ulcerative Colitis
2016 · Edward V. Loftus, Jean-Frederic Colombel, et al. · Gastroenterology · 1
Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
2023 · Jeremy S. Abramson, Scott R. Solomon, et al. · Transplantation and Cellular Therapy
Works count: 23
Citation count: 1,570
H-index: 9
I10-index: 8
Year
Topic
Type